慢性阻塞性肺疾病治疗药物研究进展
投稿时间:2016-09-27  修订日期:2017-02-23  点此下载全文
引用本文:罗志成,吴国振,袁星.慢性阻塞性肺疾病治疗药物研究进展[J].药学实践杂志,2017,35(3):201~204,242
摘要点击次数: 1251
全文下载次数: 1824
作者单位E-mail
罗志成 江西中医药大学药学院, 江西 南昌 330004  
吴国振 第二军医大学药学院, 上海 200433  
袁星 第二军医大学药学院, 上海 200433 yuanxing2012@126.com 
中文摘要:慢性阻塞性肺疾病(COPD)是一种气流受限且不完全可逆,同时病情进行性加重的慢性呼吸系统疾病。COPD病理机制复杂,病症主要包括肺功能降低、气道及肺组织慢性炎症、咳嗽、消瘦、活动量减少等。以往临床上一般采用支气管扩张剂和抗炎药物对COPD进行治疗,随着对该疾病病理机制的深入研究,抗氧化治疗也已逐渐应用于临床。笔者现对包括支气管扩张剂、抗炎药物及抗氧化治疗药物在内的COPD治疗药物的研究进展进行综述。
中文关键词:慢性阻塞性肺疾病  治疗药物  支气管扩张  抗炎  抗氧化
 
Research progress in drugs for chronic obstructive pulmonary disease therapy
Abstract:Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by incompletely reversible airflow limitation and progressive course. The pathogenesis of COPD is complicated. Clinical symptoms include declining pulmonary function, airway and lung inflammation, cough, emaciation, low activity and so on. In the past, the medications for COPD treatment were mainly bronchodilators and anti-inflammatory drugs.With the better understanding of its pathogenesis, anti-oxidative drugs have also been used in the clinical treatment of COPD recently. This article reviews the development of drugs which include bronchodilators, anti-inflammatory drugs and anti-oxidative drugs for the therapy of COPD.
keywords:COPD  drugs for therapy  bronchiectasis  anti-inflammatory  anti-oxidant
查看全文  查看/发表评论  下载PDF阅读器
关闭

分享按钮